Risk Factors for Carcinoma in situ of the Contralateral Testis in Patients with Testicular Cancer

1993 ◽  
Vol 23 (1) ◽  
pp. 115-119 ◽  
Author(s):  
S.J. Harland ◽  
P.A. Cook ◽  
S.D. Fosså ◽  
A. Horwich ◽  
M.C. Parkinson ◽  
...  
Keyword(s):  
Risk Factors ◽  
Testicular Cancer ◽  
Carcinoma In Situ ◽  
Contralateral Testis

scholarly journals Screening for carcinoma in situ of the contralateral testis in patients with germinal testicular cancer.

BMJ ◽  
1982 ◽  
Vol 285 (6356) ◽  
pp. 1683-1686 ◽  
Author(s):  
J G Berthelsen ◽  
N E Skakkebaek ◽  
H von der Maase ◽  
B L Sorensen ◽  
P Mogensen
Keyword(s):  
Testicular Cancer ◽  
Carcinoma In Situ ◽  
Contralateral Testis

Screening for Carcinoma In Situ of the Contralateral Testis in Patients With Germinal Testicular Cancer

1983 ◽  
Vol 130 (2) ◽  
pp. 404-404
Author(s):  
J.G. Berthelsen ◽  
N.E. Skakkebaek ◽  
H. von der Maase ◽  
B.L. Sørensen ◽  
P. Mogensen
Keyword(s):  
Testicular Cancer ◽  
Carcinoma In Situ ◽  
Contralateral Testis

Impaired Testicular Function in Patients With Carcinoma-In-Situ of the Testis

1999 ◽  
Vol 17 (1) ◽  
pp. 173-173 ◽  
Author(s):  
Peter Meidahl Petersen ◽  
Aleksander Giwercman ◽  
Steen W. Hansen ◽  
Jørgen G. Berthelsen ◽  
Gedske Daugaard ◽  
...  
Keyword(s):  
Testicular Cancer ◽  
Germ Cell ◽  
Leydig Cell ◽  
Carcinoma In Situ ◽  
Cell Function ◽  
Semen Quality ◽  
Sperm Concentration ◽  
Testicular Dysfunction ◽  
Leydig Cell Function

PURPOSE: To elucidate the biologic association between germ cell neoplasia and testicular dysfunction, through investigation of Leydig cell function and semen quality in men with carcinoma-in-situ (CIS) of the testis. PATIENTS AND METHODS: We examined two groups of men, unilaterally orchidectomized for testicular cancer. Biopsy of the contralateral testis had showed CIS in a group of 24 patients and no evidence of CIS in the other group of 30 patients. Semen quality and serum levels of testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were compared in these two groups of men after orchidectomy but before further treatment for testicular cancer. RESULTS: Significantly higher LH levels (median, 8.1 IU/L v 4.8 IU/L; P < .001) and generally lower testosterone levels (median, 12.5 nmol/L v 15.5 nmol/L; P = .13) were found in the CIS group. The proportion of patients with Leydig cell dysfunction was higher in the group of patients with CIS (11 of 24) than in the group of patients without (two of 30) (P = .01). Sperm concentration and total sperm count were significantly lower (P < .001) in patients with CIS (median, 0.03 × 106/mL and 0.10 × 106, respectively) than in patients without (median, 9.1 × 106/mL and 32 × 106, respectively), whereas the levels of FSH were significantly higher (P < .001) in the former group of men (median, 19.6 IU/L v 9.0 IU/L). CONCLUSION: Not only spermatogenesis but also Leydig cell function is impaired in testes with CIS. This impairment could be due to common factors in the pathogenesis of germ cell neoplasm and testicular dysfunction. Alternatively, CIS cells may have a negative impact on Leydig cell function.

scholarly journals Risk factors for the development of invasive cancer in unresected ductal carcinoma in situ

2018 ◽  
Vol 44 (4) ◽  
pp. 429-435 ◽  
Author(s):  
Anthony J. Maxwell ◽  
Karen Clements ◽  
Bridget Hilton ◽  
David J. Dodwell ◽  
Andrew Evans ◽  
...  
Keyword(s):  
Risk Factors ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Invasive Cancer
Sign in / Sign up

Export Citation Format

Share Document